Key terms
About STRO
Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest STRO news
Apr 03
9:26am ET
Sutro Biopharma price target lowered to $18 from $25 at Truist
Apr 03
8:01am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Apr 03
7:21am ET
Sutro Biopharma price target lowered to $11 from $12 at Piper Sandler
Apr 03
7:06am ET
Piper Sandler Keeps Their Buy Rating on Sutro Biopharma (STRO)
Apr 03
12:35am ET
Sutro Biopharma Buy Rating Justified by Strategic Partnerships and Promising Pipeline
Apr 02
7:43am ET
Sutro Biopharma 14.479M share Spot Secondary priced at $5.18
Apr 02
6:23am ET
Sutro Biopharma Secures Major Deal with Ipsen for STRO-003
Apr 01
1:52am ET
Sutro Biopharma (NASDAQ:STRO): Intriguing Play for Biotech Investors
Mar 28
10:59am ET
Biotech Alert: Searches spiking for these stocks today
Mar 26
8:30am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 26
4:47am ET
Sutro Biopharma: A Stable Hold Amid Pipeline Execution and Short-Term Uncertainties
Mar 26
12:25am ET
Sutro Biopharma Buy Rating Affirmed on Strong Financials and Promising Clinical Pipeline
Mar 25
10:15pm ET
TD Cowen Sticks to Its Buy Rating for Sutro Biopharma (STRO)
Feb 29
6:29am ET
Sutro Biopharma: A Balanced Hold Rating Amid Pipeline Execution and Upcoming Data Catalysts
Feb 10
4:42am ET
Sutro Biopharma Expands Share Offering, Raises $129M
Jan 22
3:50pm ET
Analysts Offer Insights on Healthcare Companies: Codexis (CDXS), Leap Therapeutics (LPTX) and Sutro Biopharma (STRO)
Jan 08
5:06am ET
Sutro Biopharma: Hold Rating Maintained Amid Near-Term Uncertainties and Market Potential Ambiguities
Jan 05
6:27am ET
Buy Rating Justified: Sutro Biopharma’s Luvelta Shows Promise in PROC Treatment and Beyond
Jan 04
4:28pm ET
Sutro Biopharma: Multi-cancer opportunity for FolRa-targeting ADC Luvelta
No recent press releases are available for STRO
STRO Financials
Key terms
Ad Feedback
STRO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
STRO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range